CN101480424B - 一种治疗前列腺疾病的药物及其制备方法 - Google Patents
一种治疗前列腺疾病的药物及其制备方法 Download PDFInfo
- Publication number
- CN101480424B CN101480424B CN2009100580646A CN200910058064A CN101480424B CN 101480424 B CN101480424 B CN 101480424B CN 2009100580646 A CN2009100580646 A CN 2009100580646A CN 200910058064 A CN200910058064 A CN 200910058064A CN 101480424 B CN101480424 B CN 101480424B
- Authority
- CN
- China
- Prior art keywords
- medicine
- herba leonuri
- catharsii molossi
- extract
- catharsii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims description 10
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 abstract description 21
- 208000013507 chronic prostatitis Diseases 0.000 abstract description 9
- 201000007094 prostatitis Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000027939 micturition Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 3
- 230000001737 promoting effect Effects 0.000 abstract 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 241000254173 Coleoptera Species 0.000 abstract 1
- 241000207925 Leonurus Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 208000025844 Prostatic disease Diseases 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 201000002327 urinary tract obstruction Diseases 0.000 abstract 1
- 241000533849 Gleditsia Species 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 229960001909 terazosin hydrochloride Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100580646A CN101480424B (zh) | 2009-01-08 | 2009-01-08 | 一种治疗前列腺疾病的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100580646A CN101480424B (zh) | 2009-01-08 | 2009-01-08 | 一种治疗前列腺疾病的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101480424A CN101480424A (zh) | 2009-07-15 |
CN101480424B true CN101480424B (zh) | 2011-04-20 |
Family
ID=40877813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100580646A Active CN101480424B (zh) | 2009-01-08 | 2009-01-08 | 一种治疗前列腺疾病的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101480424B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114099565A (zh) * | 2021-12-29 | 2022-03-01 | 成都前路通生物科技有限公司 | 一种治疗夜尿频多的药物组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1843399A (zh) * | 2006-02-14 | 2006-10-11 | 郭凯 | 一种治疗良性前列腺增生的药物及其制备方法 |
CN1989995A (zh) * | 2005-12-27 | 2007-07-04 | 郭凯 | 一种治疗良性前列腺增生的药物及其制备方法 |
-
2009
- 2009-01-08 CN CN2009100580646A patent/CN101480424B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1989995A (zh) * | 2005-12-27 | 2007-07-04 | 郭凯 | 一种治疗良性前列腺增生的药物及其制备方法 |
CN1843399A (zh) * | 2006-02-14 | 2006-10-11 | 郭凯 | 一种治疗良性前列腺增生的药物及其制备方法 |
Non-Patent Citations (4)
Title |
---|
张长城等.皂角刺皂苷对大鼠前列腺增生模型影响的实验研究.《时珍国医国药》.2008,第19卷(第8期), * |
赵书晓.良性前列腺增生症的中医药治疗概况.《中医研究》.2006,第19卷(第3期), * |
赵兴梅等.蜣螂抗实验性前列腺增生作用研究.《中药药理与临床》.2006,第22卷(第5期), * |
陈金荣等.益母草治疗前列腺增生症有效.《中医杂志》.2003,第44卷(第11期), * |
Also Published As
Publication number | Publication date |
---|---|
CN101480424A (zh) | 2009-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100364562C (zh) | 一种治疗良性前列腺增生的药物及其制备方法 | |
CN101480424B (zh) | 一种治疗前列腺疾病的药物及其制备方法 | |
CN104258051B (zh) | 一种治疗痛风性关节炎的中药组合物及其制备方法 | |
CN101391013B (zh) | 一种治疗皮肤病的中药制剂及其制备方法 | |
CN1259943C (zh) | 一种治疗前列腺增生的药物及其制备方法 | |
CN103566227B (zh) | 一种防治2型糖尿病的中药组合物及其制备方法 | |
CN103705840B (zh) | 一种治疗急慢性胆囊炎、胆石症的药物组合物及其制备方法 | |
CN102319391B (zh) | 一种治疗子宫肌瘤的中药软胶囊剂及其制备方法 | |
CN105641029A (zh) | 一种治疗膀胱出口梗阻的药物组合物及其制备方法 | |
CN101406556B (zh) | 一种用于治疗急性前列腺炎、前列腺增生的中药制剂及其制备方法 | |
CN101897714B (zh) | 芍药苷的用途 | |
CN100455309C (zh) | 一种治疗妇科炎症的复方中药制剂及其制备方法 | |
CN1989995A (zh) | 一种治疗良性前列腺增生的药物及其制备方法 | |
CN103919794A (zh) | 人参皂苷Rh1在制备改善糖皮质激素抵抗药物中的应用 | |
CN104800811B (zh) | 一种治疗或预防前列腺增生的组合物及其应用 | |
CN101214316A (zh) | 北方栽培的假酸浆子(单方)水煎服能治慢性肾病 | |
CN102940655B (zh) | 治疗前列腺增生的药物组合物 | |
CN102552481A (zh) | 一种通络降压中药组合物及其制备方法 | |
CN106389799A (zh) | 一种治疗原发性痛经的中药制剂及其制备方法及用途 | |
CN102335393B (zh) | 一种用于前列腺的保健品 | |
CN102961680B (zh) | 一种治疗胆结石、胆囊炎的中药制剂及其制备方法 | |
CN102961678B (zh) | 一种治疗胆结石、胆囊炎的中药制剂及其制备方法 | |
CN101190265A (zh) | 一种治疗子宫内膜异位症的药物及其制备方法 | |
CN102961679B (zh) | 一种治疗胆结石、胆囊炎的中药制剂及其制备方法 | |
CN104644769A (zh) | 一种中药组合物在制备治疗前列腺炎药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Guo Kai Document name: Notice of application for publication of patent for invention and entry into the substantive examination procedure |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 610041 Chengdu City, Sichuan province high tech Zone, Century City Road, Longhu century Feng Jing, building 1, unit 3703, 7 Patentee after: Guo Kai Address before: 610045 Sichuan city of Chengdu province Wuhou District Wu Xing Road No. two building 8, unit 6, notting hill 10 floor, No. 1002 Patentee before: Guo Kai |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180906 Address after: 610045 1 building, nine Hing Avenue, Chengdu high tech Zone, Chengdu, Sichuan, China. 10 Patentee after: Chengdu front road Biotechnology Co., Ltd. Address before: 610041 Sichuan city Chengdu high tech Zone Century City Road Longhu century peak 7 buildings 1 units 3703 Patentee before: Guo Kai |